SCHEMBL4515693

SCHEMBL4515693

CCOC(=O)c1sc2nc(Cc3ccc(Cl)c(Cl)c3)[nH]c(=S)c2c1C

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.80
RXFP1 Q9HBX9 3/20 0.80
LMNA P02545 3/20 0.80
NPSR1 Q6W5P4 2/20 0.80
KCNH2 Q12809 1/20 0.80
MAPT P10636 4/20 0.61
PPARG P37231 1/20 0.61
NCOA2 Q15596 1/20 0.61
ALDH1A1 P00352 5/20 0.52
MEN1 O00255 4/20 0.52
PIP4K2A P48426 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 7/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
STAT3 P40763 1/20 0.44
USP2 O75604 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4511459 0.91 KMT2A (0.79) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4514505 0.89 KMT2A (0.65) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL3492427 0.88 KMT2A (0.60) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4520845 0.87 KMT2A (0.78) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4527847 0.84 KMT2A (0.80) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4517936 0.83 KMT2A (0.69) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4510382 0.82 KMT2A (0.54) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4511802 0.82 KMT2A (0.73) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4520410 0.81 KMT2A (0.66) KMT2ARXFP1LMNANPSR1KCNH2
SCHEMBL4512178 0.81 KDM4E (0.58) KMT2ARXFP1LMNANPSR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 KMT2A 2650/4885RXFP1 739/4885LMNA 4474/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 KMT2A 2650/4885RXFP1 739/4885LMNA 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.